Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.61 |
| ▸ | GPR34 | Q9UPC5 | 8/20 | 0.60 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CPA1 | P15085 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24023494 | 0.84 | PPARG (0.68) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL3796711 | 0.83 | ITGB3 (0.47) | PPARGGPR34MMEACECPA1 | |
| SCHEMBL2030203 | 0.83 | PPARG (0.67) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL8760872 | 0.83 | PPARG (0.67) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL2035189 | 0.83 | PPARG (0.67) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL8413776 | 0.82 | PPARG (0.62) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL1855602 | 0.82 | PPARG (0.62) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL6034470 | 0.82 | PPARG (0.62) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL6034466 | 0.82 | PPARG (0.62) | PPARGGPR34PPARAMMEACE | |
| SCHEMBL8413779 | 0.82 | PPARG (0.62) | PPARGGPR34PPARAMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| US-12269900-B2 | Inhibitors of β integrin-G protein α subunit binding interactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-04-08 | — | — | US | disclosed |
| US-20250073355-A1 | CD44-BINDING PEPTIDE REAGENTS AND METHODS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-03-06 | — | — | US | disclosed |
| CN-110831634-B | Glypican-3 peptide reagents and methods | 密歇根大学董事会 | 2024-07-02 | — | — | CN | disclosed |
| US-11939369-B2 | Integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-11830582-B2 | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents | UNIVERSITY OF MIAMI (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-102088989-A | Glucagon analogs with enhanced solubility and stability in physiological pH buffers | UNIV INDIANA RES & TECH CORP | 2011-06-08 | — | — | CN | disclosed |
| EP-2300035-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7858349-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010127381-A1 | DIAGNOSIS, MONITORING, PROGNOSIS, PREVENTION AND TREATMENT OF ANEURYSMS | JAMES COOK UNIVERSITY (AU) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010111617-A2 | PARATHYROID HORMONE PEPTIDES AND PARATHYROID HORMONE-RELATED PROTEIN PEPTIDES AND METHODS OF USE | VAN ANDEL RESEARCH INSTITUTE (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010011439-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090088454-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-04-02 | — | — | US | disclosed |
| US-7427496-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-09-23 | — | — | US | disclosed |
| US-20060183772-A1 | To inhibit tumor growth in an animal; to induce apoptosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939369-B2 | Integrin antagonists | ITGB3, ITGA2B, ITGB1 | PPARG 3972/4885GPR34 2014/4885PPARA 3975/4885 |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | PPARG 1653/4885GPR34 1725/4885PPARA 2919/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | PPARG 2391/4885GPR34 1957/4885PPARA 2911/4885 |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | MMP1, MMP8, COL2A1 | PPARG 944/4885GPR34 3602/4885PPARA 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.